We are analyzing https://link.springer.com/article/10.1007/s12272-024-01494-1.

Title:
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress | Archives of Pharmacal Research
Description:
The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical trials for cancer therapy. However, owing to disadvantages such as organ toxicity and drug resistance, only one HSP90 inhibitor has been approved for use in clinical settings. In recent years, HSP90 inhibitors used in combination with other anti-cancer therapies have shown remarkable potential in the treatment of cancer. HSP90 inhibitors work synergistically with various anti-cancer therapies, including chemotherapy, targeted therapy, radiation therapy and immunotherapy. HSP90 inhibitors can improve the pharmacological effects of the above-mentioned therapies and reduce treatment resistance. This review provides an overview of the use of combination therapy with HSP90 inhibitors and other anti-cancer therapies in clinical and preclinical studies reported in the past decade and summarises design strategies and prospects for these combination therapies. Altogether, this review provides a theoretical basis for further research and application of these combination therapies in the treatment of cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

pubmed, article, google, scholar, cas, cancer, hsp, central, inhibitor, liu, inhibitors, inhibition, therapy, combination, cell, resistance, heat, shock, protein, oncol, phase, res, mol, patients, clin, cells, med, drug, chen, httpsdoiorgs, zhang, ganetespib, wang, study, treatment, int, lung, advanced, ther, breast, chem, tumors, sci, clinical, httpsdoiorgccr, targeting, anticancer, httpsdoiorg, front, pharmacol,

Topics {✒️}

fragment-based x-ray crystallography impede nf-κb/p65 signaling brafv600e-mutant high-grade glioma month download article/chapter her2-amplified trastuzumab-resistant breast 3rd-generation egfr-tki resistance her2-positive breast cancer anti-androgen hormonal therapy pi3k/mtor dual inhibitor relapsed/refractory multiple myeloma cytokine-induced killer cells induce p53-mediated apoptosis hyperthermia-based anticancer treatments targets drug-resistant pathways nanomaterial-based combination immunotherapy small-cell lung cancer hyperthermia-based cancer treatments inducing p53-mediated apoptosis anti-tumor immune mechanisms hyperthermia-induced dna damage radiation-induced tumor vasculogenesis stat3/hif-1α signaling central universities [grant 1-methyl-1 h-pyrazol-4-yl full article pdf braf-mutant solid tumors antibody-drug conjugate pharmacal research aims anti-cancer therapies heat shock protein homologous recombination resulting molecular targeted therapy cancer drug resistance heat shock response egfr-targeted therapies line maintenance therapy synergistic antitumor effects reversing drug resistance hinson jm jr hsp90 overcomes resistance rapamycin inhibits growth dhea promoting apoptosis privacy choices/manage cookies b-cell malignancies shutao tan revised immune checkpoint therapy lung cancer cells overcoming drug resistance van besien hj braf inhibitor therapy

Questions {❓}

Graner MW (2021) Making HSP90 inhibitors great again?
Pennisi R, Ascenzi P, di Masi A (2016) Hsp90: a new player in DNA repair?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
         description:The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical trials for cancer therapy. However, owing to disadvantages such as organ toxicity and drug resistance, only one HSP90 inhibitor has been approved for use in clinical settings. In recent years, HSP90 inhibitors used in combination with other anti-cancer therapies have shown remarkable potential in the treatment of cancer. HSP90 inhibitors work synergistically with various anti-cancer therapies, including chemotherapy, targeted therapy, radiation therapy and immunotherapy. HSP90 inhibitors can improve the pharmacological effects of the above-mentioned therapies and reduce treatment resistance. This review provides an overview of the use of combination therapy with HSP90 inhibitors and other anti-cancer therapies in clinical and preclinical studies reported in the past decade and summarises design strategies and prospects for these combination therapies. Altogether, this review provides a theoretical basis for further research and application of these combination therapies in the treatment of cancer.
         datePublished:2024-04-17T00:00:00Z
         dateModified:2024-04-17T00:00:00Z
         pageStart:442
         pageEnd:464
         sameAs:https://doi.org/10.1007/s12272-024-01494-1
         keywords:
            HSP90 inhibitors
            Cancer therapy
            Drug combination
            Synergistic effect
            Drug resistance
            Pharmacy
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-024-01494-1/MediaObjects/12272_2024_1494_Fig1_HTML.png
         isPartOf:
            name:Archives of Pharmacal Research
            issn:
               1976-3786
               0253-6269
            volumeNumber:47
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Pharmaceutical Society of Korea
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yajun Liu
               url:http://orcid.org/0000-0002-9539-7279
               affiliation:
                     name:Shenyang Pharmaceutical University
                     address:
                        name:School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Chenyao Li
               affiliation:
                     name:Dalian University of Technology
                     address:
                        name:School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hongwei Liu
               affiliation:
                     name:Liaoning Cancer Hospital and Institute
                     address:
                        name:Department of Head and Neck Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China
                        type:PostalAddress
                     type:Organization
                     name:Affiliated Cancer Hospital of Dalian University of Technology
                     address:
                        name:Affiliated Cancer Hospital of Dalian University of Technology, Shenyang, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Shutao Tan
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
      description:The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical trials for cancer therapy. However, owing to disadvantages such as organ toxicity and drug resistance, only one HSP90 inhibitor has been approved for use in clinical settings. In recent years, HSP90 inhibitors used in combination with other anti-cancer therapies have shown remarkable potential in the treatment of cancer. HSP90 inhibitors work synergistically with various anti-cancer therapies, including chemotherapy, targeted therapy, radiation therapy and immunotherapy. HSP90 inhibitors can improve the pharmacological effects of the above-mentioned therapies and reduce treatment resistance. This review provides an overview of the use of combination therapy with HSP90 inhibitors and other anti-cancer therapies in clinical and preclinical studies reported in the past decade and summarises design strategies and prospects for these combination therapies. Altogether, this review provides a theoretical basis for further research and application of these combination therapies in the treatment of cancer.
      datePublished:2024-04-17T00:00:00Z
      dateModified:2024-04-17T00:00:00Z
      pageStart:442
      pageEnd:464
      sameAs:https://doi.org/10.1007/s12272-024-01494-1
      keywords:
         HSP90 inhibitors
         Cancer therapy
         Drug combination
         Synergistic effect
         Drug resistance
         Pharmacy
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12272-024-01494-1/MediaObjects/12272_2024_1494_Fig1_HTML.png
      isPartOf:
         name:Archives of Pharmacal Research
         issn:
            1976-3786
            0253-6269
         volumeNumber:47
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Pharmaceutical Society of Korea
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yajun Liu
            url:http://orcid.org/0000-0002-9539-7279
            affiliation:
                  name:Shenyang Pharmaceutical University
                  address:
                     name:School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Chenyao Li
            affiliation:
                  name:Dalian University of Technology
                  address:
                     name:School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hongwei Liu
            affiliation:
                  name:Liaoning Cancer Hospital and Institute
                  address:
                     name:Department of Head and Neck Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China
                     type:PostalAddress
                  type:Organization
                  name:Affiliated Cancer Hospital of Dalian University of Technology
                  address:
                     name:Affiliated Cancer Hospital of Dalian University of Technology, Shenyang, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Shutao Tan
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Archives of Pharmacal Research
      issn:
         1976-3786
         0253-6269
      volumeNumber:47
Organization:
      name:Pharmaceutical Society of Korea
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shenyang Pharmaceutical University
      address:
         name:School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China
         type:PostalAddress
      name:Dalian University of Technology
      address:
         name:School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China
         type:PostalAddress
      name:Liaoning Cancer Hospital and Institute
      address:
         name:Department of Head and Neck Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China
         type:PostalAddress
      name:Affiliated Cancer Hospital of Dalian University of Technology
      address:
         name:Affiliated Cancer Hospital of Dalian University of Technology, Shenyang, China
         type:PostalAddress
      name:Shengjing Hospital of China Medical University
      address:
         name:Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yajun Liu
      url:http://orcid.org/0000-0002-9539-7279
      affiliation:
            name:Shenyang Pharmaceutical University
            address:
               name:School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Chenyao Li
      affiliation:
            name:Dalian University of Technology
            address:
               name:School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China
               type:PostalAddress
            type:Organization
      name:Hongwei Liu
      affiliation:
            name:Liaoning Cancer Hospital and Institute
            address:
               name:Department of Head and Neck Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China
               type:PostalAddress
            type:Organization
            name:Affiliated Cancer Hospital of Dalian University of Technology
            address:
               name:Affiliated Cancer Hospital of Dalian University of Technology, Shenyang, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Shutao Tan
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China
      name:School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China
      name:Department of Head and Neck Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China
      name:Affiliated Cancer Hospital of Dalian University of Technology, Shenyang, China
      name:Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(764)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.2s.

LINK . SPRINGER . COM {}